Show simple item record

dc.contributor.authorHideshima, Teru
dc.contributor.authorBradner, James E.
dc.contributor.authorWong, Jason
dc.contributor.authorChauhan, Dharminder
dc.contributor.authorRichardson, Paul
dc.contributor.authorSchreiber, Stuart L.
dc.contributor.authorAnderson, Kenneth C.
dc.date.accessioned2019-10-03T17:42:19Z
dc.date.issued2005
dc.identifier.citationHideshima, T., J. E. Bradner, J. Wong, D. Chauhan, P. Richardson, S. L. Schreiber, and K. C. Anderson. 2005. “Small-Molecule Inhibition of Proteasome and Aggresome Function Induces Synergistic Antitumor Activity in Multiple Myeloma.” Proceedings of the National Academy of Sciences 102 (24): 8567–72. https://doi.org/10.1073/pnas.0503221102.
dc.identifier.issn0027-8424
dc.identifier.issn0744-2831
dc.identifier.issn1091-6490
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:41467492*
dc.description.abstractWe have shown that the proteasome inhibitor bortezomib (formerly known as PS-341) triggers significant antitumor activity in multiple myeloma (MM) in both preclinical models and patients with relapsed refractory disease. Recent studies have shown that unfolded and misfolded ubiquitinated proteins are degraded not only by proteasomes, but also by aggresomes, dependent on histone deacetylase 6 (HDAC6) activity. We therefore hypothesized that inhibition of both mechanisms of protein catabolism could induce accumulation of ubiquitinated proteins followed by significant cell stress and cytotoxicity in MM cells. To prove this hypothesis, we used bortezomib and tubacin to inhibit the proteasome and HDAC6, respectively. Tubacin specifically triggers acetylation of alpha-tubulin as a result of HDAC6 inhibition in a dose- and time-dependent fashion. It induces cytotoxicity in MM cells at 72 h with an IC50 of 5-20 mu M, which is mediated by caspase-dependent apoptosis; no toxicity is observed in normal peripheral blood mononuclear cells. Tubacin inhibits the interaction of HDAC6 with dynein and induces marked accumulation of ubiquitinated proteins. It synergistically augments bortezomib-induced cytotoxicity by c-Jun NH2-terminal kinase/caspase activation. Importantly, this combination also induces significant cytotoxicity in plasma cells isolated from MM patient bone marrow. Finally, adherence of MM cells to bone marrow stromal cells confers growth and resistance to conventional treatments; in contrast, the combination of tubacin and bortezomib triggers toxicity even in adherent MM cells. Our studies therefore demonstrate that tubacin combined with bortezomib mediates significant anti-MM activity, providing the framework for clinical evaluation of combined therapy to improve patient outcome in MM.
dc.language.isoen_US
dc.publisherNational Academy of Sciences
dash.licenseLAA
dc.titleSmall-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
dc.typeJournal Article
dc.description.versionVersion of Record
dc.relation.journalProceedings of the National Academy of Sciences of the United States of America
dash.depositing.authorSchreiber, Stuart L.::80f648d0514e642a8f97bb9b12b10db7::600
dc.date.available2019-10-03T17:42:19Z
dash.workflow.comments1Science Serial ID 86979
dc.identifier.doi10.1073/pnas.0503221102
dash.source.volume102;24
dash.source.page8567


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record